Navigation Links
Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
Date:6/2/2009

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave(R) (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the American Diabetes Association (ADA) 69th Scientific Sessions, June 5-9, 2009, and the 91st Annual Meeting of the Endocrine Society (ENDO), June 10-13, 2009.

ADA: Ernest N. Morial Convention Center, New Orleans, LA.

    Saturday, June 6:  Embargo Lifts June 6 at 9:00 a.m. CT
    Oral Presentation
    Abstract: 37-OR
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, PA
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss:
    A 56-week Phase 3 Study"
    Time: 9:00 a.m. CT
    Location: Room 255

    Monday, June 8:  Embargo Lifts June 6 at 10:00 a.m. CT
    Poster Presentation*
    Abstract: 1731-P
    Presenter: Thomas A. Wadden, Ph.D., University of Pennsylvania School of
    Medicine, Philadelphia, Pa.
    Title: "Naltrexone + Bupropion Combination Causes Weight Loss and Improves
    Quality of Life"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    Poster Presentation*
    Abstract: 1730-P
    Presenter: Samuel Klein, M.D., Washington University School of Medicine,
    St. Louis, Mo.
    Title: "Naltrexone + Bupropion Combination Causes Significant Weight Loss
    Without Worsening Psychiatric Symptoms"
    Time: 12:00 - 2:00 p.m. CT
    Location: Hall E

    * Posters will also be presented Sunday, June 7 from 6:30 - 7:45 p.m. CT
    at a Poster Reception in Hall E

ENDO: Walter E. Washington Convention Center, Washington,
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... immune system identifies the transplanted organ as foreign tissue ... cells, the immune cells that mediate rejection, must first ... to migrate to the transplanted organ. In this issue ... Lakkis and colleagues at the University of Pittsburgh used ... is not required for migration. Instead, these cells must ...
(Date:5/17/2013)... New interactive learning forums ... leaders of the medical device industry at the ... expo, from June 18-20 in Philadelphia ... ) , These all-new MedTech ... practical presentations and implementable solutions on the most ...
(Date:5/17/2013)... Miami, FL (PRWEB) May 17, 2013 Men’s ... at La-roche Posay ) and has been known ... itself. Although some men may be far from puberty, other ... be clogging pores, causing breakouts, and threatening skin with unsightly ... with advice from Men’s Health on how to ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... Expand Versatility of DelSite cGMP Polymer, ... (Pink Sheets: CARN) today announced its wholly-owned,subsidiary, ... rights license agreement with a biotechnology company ... DelSite,s,high-molecular-weight anionic polysaccharide which is produced under ...
... 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), a special ... Co., Ltd (Kelun), China,s largest producer of,intravenous (IV) ... highlights with respect to the consolidated results of,operations ... entity,(Kelun Group) for the first half of 2007. ...
... PARSIPPANY, N.J., Sept. 19 Over 20 new ... Biotech Competitive Intelligence &,Business Analysis" conference in two ... standard for pharmaceutical CI, Business Analysis, and Market,Forecasting ... gather on,October 1-2 to attend the meeting. Competition ...
Cached Biology Technology:Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 2Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2
(Date:5/17/2013)... Ill. An international team of ... structure and cell movement inside a living frog embryo ... a new method to advance biological research and the ... Northwestern University and the Karlsruher Institut fr Technologie in ... the U.S. Department of Energy,s Argonne National Laboratory, released ...
(Date:5/16/2013)... MARC (Maximizing Access to Research Careers) Program has ... for Developmental Biology (SDB) 72nd Annual Meeting in ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... SDB 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... University scientists have shown a gene involved in neurodegenerative ... function of the circadian clock. , In a ... the gene, called Ataxin-2, keeps the clock responsible for ... gene, the rhythm of the fruit fly,s sleep-wake cycle ... difficult for the fly. , The discovery is ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Gene involved in neurodegeneration keeps clock running 2
... in the September issue of the Journal of Lipid ... a role in the rising rate of diabetes, especially in ... is the primary mechanism of inheritance; kids get half their ... just starting to understand additional kinds of inheritance like metabolic ...
... a group of University of Oklahoma researchers began studying ... has plagued the energy industry for decades, they did ... capable of converting hydrocarbons into natural gas. ... hydrocarbon metabolismcan be used to stimulate methane gas production ...
... received a $3.2 million grant from the National ... and mathematical disciplines to stem cell research. In ... experts in fields such as cell and molecular ... breakthroughs from the biology lab into practical and ...
Cached Biology News:OU researchers isolate microorganisms that convert hydrocarbons to natural gas 2OU researchers isolate microorganisms that convert hydrocarbons to natural gas 3$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 2$3.2M for Rutgers to apply biology, engineering, physical sciences toward stem cells 3
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
pETDuet-1 is designed for the coexpression of two target genes....
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Mouse Laminin-1 MAb (Clone AL-3)...
Biology Products: